ADMA BIOLOGICS, INC. : Other Events (form 8-K)

Item 8.01 Other Events

On January 4, 2021, ADMA Biologics, Inc. (the "Company") announced that the Centers for Medicare and Medicaid Services (CMS) has approved transitional pass-through payment status and established a new reimbursement C-code, C9072, for ASCENIV which is effective January 1, 2021. A copy of the Company's press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein.

Item 9.01 Exhibits.




(d) Exhibits



Exhibit No. Description

99.1 Press Release of the Company, dated January 4, 2021 104 Cover Page Interactive Data File (embedded with the Inline XBRL Document)

© Edgar Online, source Glimpses